Management of Alcohol Withdrawal with Phenobarbital

Guideline-Based Framework

The American College of Medical Toxicology recommends long-acting benzodiazepines, such as diazepam and chlordiazepoxide, as first-line treatment for alcohol withdrawal, due to their established efficacy in reducing withdrawal symptoms and preventing seizures and delirium tremens 1
Short-acting benzodiazepines, such as lorazepam and oxazepam, are preferred in elderly patients and those with hepatic dysfunction 1
Benzodiazepines are considered the mainstay of treatment despite uncertainty about their effectiveness and safety in all patients, according to the Society of Critical Care Medicine 2

The Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale should be used to guide treatment intensity, with scores >8 indicating moderate withdrawal and ≥15 indicating severe withdrawal requiring aggressive treatment, as recommended by the American Society of Addiction Medicine 1
Thiamine (100-300 mg/day) should be administered concurrently to prevent Wernicke encephalopathy, according to the National Institute on Alcohol Abuse and Alcoholism 1

In patients with hepatic dysfunction, phenobarbital may offer advantages over benzodiazepines that undergo hepatic metabolism, though this requires careful monitoring, as suggested by the American Association for the Study of Liver Diseases 1
Elderly patients require particular caution with any sedative agent, including phenobarbital, due to the increased risk of adverse effects, according to the American Geriatrics Society 1
Patients with psychiatric comorbidities, such as depression or anxiety, should receive concurrent treatment for these conditions, as recommended by the American Psychiatric Association 3